pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

braeburn PRESS RELEASE ARCHIVE

Jun 12, 2023

Braeburn Whisky, Trusted Whisky Cask Investment Experts, Launch in United States

May 23, 2023

Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

Dec 8, 2022

FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

Oct 14, 2022

NLRB to Prosecute Braeburn Alloy Steel over Unfair Labor Practices

Jun 26, 2021

FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

Jun 15, 2021

Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder

Jun 15, 2021

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Dec 10, 2020

Braeburn Announces Arbitration Determination that It Did Not Materially Breach Its License Agreement with Camurus AB

Jun 1, 2020

Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder

Nov 7, 2019

FDA Grants Braeburn's Citizen Petition Allowing BRIXADI (buprenorphine) Extended-Release Injection for Opioid Use Disorder to be Available in December 2020

Nov 7, 2019

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From the US market

Jun 4, 2019

Braeburn Announces Publication of Phase 3 Study Results Showing Long-term Safety and Effectiveness of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder

Apr 9, 2019

Braeburn Initiates Court Proceedings to Overturn Exclusivity and Seeks Immediate Market Approval of Brixadi™ in the US

Dec 23, 2018

Braeburn Announces Tentative FDA Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Moderate to Severe Opioid Use Disorder

Sep 18, 2018

Braeburn Announces Positive Top-line Phase 3 Results for CAM2038 in Chronic Low Back Pain Patients Previously on Long-term Daily Opioid Therapy

Jul 16, 2018

Braeburn Announces PDUFA Date for CAM2038 for the Treatment of Opioid Use Disorder

Jun 25, 2018

Braeburn Appoints Richard Malamut, M.D. as Chief Medical Officer

May 30, 2018

Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine For Opioid Dependence

May 28, 2018

Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder

May 14, 2018

Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine

Apr 12, 2018

Braeburn Launches Brave Action

Jan 22, 2018

Titan In Discussions With Braeburn Regarding U.S. Probuphine Commercialization

Jan 21, 2018

Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot for the Treatment of Opioid Use Disorder

Nov 1, 2017

Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder

Oct 5, 2017

Braeburn CEO Participates in U.S. Department of Health and Human Services Secretarial Roundtable Discussion on Opioids

Sep 27, 2017

Braeburn Participates in President's Commission Meeting on Combating Drug Addiction and the Opioid Crisis

Sep 18, 2017

Braeburn Announces FDA Acceptance with Priority Review of New Drug Application for CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder

Jul 20, 2017

Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder

Jun 15, 2017

Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine

Jun 13, 2017

Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE in Canada for Opioid Drug Dependence

Jun 13, 2017

Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE(R) in Canada for Opioid Drug Dependence

Jun 13, 2017

Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE(R) in Canada for Opioid Drug Dependence

Jun 5, 2017

Braeburn Pharmaceuticals Names Michael M. Derkacz as President and CEO

May 2, 2017

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038

May 2, 2017

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038

May 2, 2017

Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Phase 3 Safety Study of CAM2038

Apr 26, 2017

Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia

Mar 31, 2017

Braeburn Pharmaceuticals Applauds Repeal of HB2

Feb 13, 2017

Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech

Jan 13, 2017

Braeburn Pharmaceuticals' Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services

Nov 21, 2016

Braeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year

Nov 14, 2016

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction

Nov 14, 2016

Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine for Treatment of Opioid Addiction

Nov 14, 2016

Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction

Oct 24, 2016

Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea

Oct 24, 2016

Camurus AB: Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea

Oct 21, 2016

Braeburn Pharmaceuticals and Camurus announce the presentation of new data from clinical studies of long-acting buprenorphine

Oct 17, 2016

Braeburn Pharmaceuticals to Conduct Series of Probuphine (buprenorphine) Implant Trainings in Salt Lake City on October 27-29, 2016 for Qualified Healthcare Providers

Oct 17, 2016

Braeburn Pharmaceuticals to Conduct Series of Probuphine® (buprenorphine) Implant Trainings in Baltimore on October 26-28, 2016 for Qualified Healthcare Providers

Sep 30, 2016

Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for Treatment of Chronic Low Back Pain

Sep 30, 2016

Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for treatment of Chronic Low Back Pain

Aug 2, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in San Juan on August 5, 6 and 7 for Qualified Healthcare Providers

Jul 26, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Burlington on July 29 and 30 for Qualified Healthcare Providers

Jul 26, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Las Vegas on July 29, 30 and 31 for Qualified Healthcare Providers

Jul 19, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Houston on July 22, 23 and 24 for Qualified Healthcare Providers

Jul 19, 2016

Braeburn Pharmaceuticals Announces Probuphine Data Published in the Journal of the American Medical Association

Jul 19, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Nashville on July 22, 23 and 24 for Qualified Healthcare Providers

Jul 19, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Oklahoma City on July 22, 23 and 24 for Qualified Healthcare Providers

Jul 19, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Jacksonville on July 22, 23 and 24 for Qualified Healthcare Providers

Jul 19, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Honolulu on July 22 and 23 for Qualified Healthcare Providers

Jul 19, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Seattle on July 22, 23 and 24 for Qualified Healthcare Providers

Jul 12, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Dallas on July 15, 16 and 17 for Qualified Healthcare Providers

Jul 12, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Denver on July 15, 16 and 17 for Qualified Healthcare Providers

Jul 12, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Anchorage on July 18 and 19 for Qualified Healthcare Providers

Jul 12, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Birmingham on July 15, 16 and 17 for Qualified Healthcare Providers

Jul 12, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Memphis on July 15, 16 and 17 for Qualified Healthcare Providers

Jul 12, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Richmond on July 15, 16 and 17 for Qualified Healthcare Providers

Jun 29, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Grand Rapids on July 8 and 9 for Qualified Healthcare Providers

Jun 29, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Charleston on July 8, 9 and 10 for Qualified Healthcare Providers

Jun 29, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Orlando on July 8, 9 and 10 for Qualified Healthcare Providers

Jun 29, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in New Orleans on July 8, 9 and 10 for Qualified Healthcare Providers

Jun 29, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Albany on July 8 and 9 for Qualified Healthcare Providers

Jun 29, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Atlanta on July 8, 9 and 10 for Qualified Healthcare Providers

Jun 29, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Antonio on July 8 and 9 for Qualified Healthcare Providers

Jun 21, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Columbus on June 24, 25 and 26 for Qualified Healthcare Providers

Jun 21, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Manchester on June 24, 25 and 26 for Qualified Healthcare Providers

Jun 21, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Philadelphia on June 24, 25 and 26 for Qualified Healthcare Providers

Jun 21, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Los Angeles on June 24, 25 and 26 for Qualified Healthcare Providers

Jun 21, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Portland on June 24, 25 and 26 for Qualified Healthcare Providers

Jun 21, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in St. Louis on June 24 and 25 for Qualified Healthcare Providers

Jun 21, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Minneapolis on June 24, 25 and 26 for Qualified Healthcare Providers

Jun 20, 2016

Seventeen Days after Receiving FDA Approval, Braeburn Pharmaceuticals Announces First Patients Have Received Probuphine (buprenorphine) Implant

Jun 14, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Francisco on June 17, 18 and 19 for Qualified Healthcare Providers

Jun 14, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Indianapolis on June 17 and 18 for Qualified Healthcare Providers

Jun 14, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Chicago on June 17, 18 and 19 for Qualified Healthcare Providers

Jun 14, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Washington, D.C. on June 17, 18 and 19 for Qualified Healthcare Providers

Jun 9, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Rochester on June 10, 11 and 12 for Qualified Healthcare Providers

Jun 9, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Boston on June 10, 11 and 12 for Qualified Healthcare Providers

Jun 9, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Baltimore on June 10, 11 and 12 for Qualified Healthcare Providers

Jun 9, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Cleveland on June 10, 11 and 12 for Qualified Healthcare Providers

Jun 9, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Miami on June 10, 11 and 12 for Qualified Healthcare Providers

Jun 9, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Louisville on June 10, 11 and 12 for Qualified Healthcare Providers

Jun 9, 2016

Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Albuquerque on June 10, 11 and 12 for Qualified Healthcare Providers

May 31, 2016

Braeburn Pharmaceuticals Announces Commercialization Plans for Probuphine (buprenorphine) Implant, Six-Month Treatment for Opioid Dependence

May 26, 2016

Braeburn Pharmaceuticals Announces FDA Approves Probuphine (buprenorphine) Implant: The First Implant for Treatment of Opioid Dependence

May 17, 2016

Braeburn Pharmaceuticals Announces Decision to Continue with North Carolina Manufacturing Facility Plans

May 11, 2016

Braeburn Pharmaceuticals and Camurus announce positive top line results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder

May 11, 2016

Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Results from Phase 2 Opioid Challenge Study with CAM2038 in Subjects with Opioid Use Disorder

Apr 5, 2016

Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence

Apr 5, 2016

Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence

Feb 22, 2016

Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain

Feb 22, 2016

Camurus AB: Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain

Feb 1, 2016

Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE®

Jan 12, 2016

Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction

Dec 30, 2015

Braeburn Pharmaceuticals and Camurus Enroll First Patient in a Phase 3 Efficacy Trial of Long-acting Treatment for Opioid Dependence

Dec 15, 2015

Braeburn Pharmaceuticals and Camurus announce start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence

Dec 15, 2015

Camurus AB: Braeburn Pharmaceuticals and Camurus Announces Start of Phase 3 Trial of Long-Acting Buprenorphine Treatments for Opioid Dependence

Dec 9, 2015

Braeburn Pharmaceuticals And Titan Pharmaceuticals Announce Date Of FDA Advisory Committee Review Of Probuphine For Opioid Addiction

Nov 9, 2015

Dr. Frank Young of Braeburn Pharmaceuticals Receives 2015 Distinguished Scientist Award from American College of Toxicology

Oct 22, 2015

Braeburn Pharmaceuticals Commends President Obama's Commitment to Improving Treatment for Opioid Addiction

Sep 28, 2015

Braeburn Announces FDA's Acknowledgment of Receipt of Probuphine® NDA Resubmission; Agency Action Expected by February 27, 2016

Sep 17, 2015

Braeburn Pharmaceuticals Commends HHS Secretary Burwell for Initiative to Expand Access to Medication-Assisted Treatment for Opioid Addiction

Jun 8, 2015

Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction

May 1, 2015

Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments

Nov 20, 2014

Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain Sverige - English USA - English

Sep 24, 2014

Braeburn Pharmaceuticals' Probuphine Study Hits Enrollment Milestone

Jul 21, 2014

Braeburn Pharmaceuticals Enrolls First Patients In Late-Stage Clinical Study Of Probuphine For Opioid Dependence

Apr 30, 2014

Braeburn Pharmaceuticals to Initiate New Clinical Study for Probuphine Following Clear Guidance from FDA

Feb 14, 2014

Acacia Subsidiary Enters into Patent License Agreement with Braeburn Systems LLC

Sep 11, 2013

Frank E. Young, Former FDA Commissioner, Joins Braeburn Pharmaceuticals as EVP, Clinical and Regulatory Affairs

Google Analytics Alternative